You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞盛醫藥(06855.HK)與默沙東達成一項實體瘤聯合用藥臨床研究合作
阿思達克 07-06 12:15
亞盛醫藥(06855.HK)公布,與默沙東(MSD)已達成一項臨床研究合作。雙方將就亞盛醫藥在研原創MDM2-p53抑制劑APG-115與默沙東的PD-1單抗KEYTRUDA(pembrolizumab)的聯合治療展開臨床研究,以評估該聯合用藥在晚期實體瘤患者中的臨床效果。

基於合作協議,亞盛醫藥將支持該項開放性Ib/II期臨床研究(NCT03611868),以評估APG-115聯合KEYTRUDA治療多種實體瘤(如非小細胞肺癌、黑色素瘤、尿路上皮癌、脂肪瘤、惡性周圍神經鞘瘤和經PD-1/PD-L1治療產生耐藥或復發、以及未經過PD-1/PD-L1治療的ATM突變╱Tp53野生型腫瘤)患者的安全性和有效性。該研究的II期階段已開始,並計劃在美國各地共招募80名患者。亞盛醫藥與默沙東將採用聯合開發委員會交換研究信息。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account